27 research outputs found

    The CADM1 tumor suppressor gene is a major candidate gene in MDS with deletion of the long arm of chromosome 11.

    Get PDF
    Myelodysplastic syndromes (MDS) represent a heterogeneous group of clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis leading to peripheral cytopenias and in a substantial proportion of cases to acute myeloid leukemia. The deletion of the long arm of chromosome 11, del(11q), is a rare but recurrent clonal event in MDS. Here, we detail the largest series of 113 cases of MDS and myelodysplastic syndromes/myeloproliferative neoplasms (MDS/MPN) harboring a del(11q) analyzed at clinical, cytological, cytogenetic, and molecular levels. Female predominance, a survival prognosis similar to other MDS, a low monocyte count, and dysmegakaryopoiesis were the specific clinical and cytological features of del(11q) MDS. In most cases, del(11q) was isolated, primary and interstitial encompassing the 11q22-23 region containing ATM, KMT2A, and CBL genes. The common deleted region at 11q23.2 is centered on an intergenic region between CADM1 (also known as Tumor Suppressor in Lung Cancer 1) and NXPE2. CADM1 was expressed in all myeloid cells analyzed in contrast to NXPE2. At the functional level, the deletion of Cadm1 in murine Lineage-Sca1+Kit+ cells modifies the lymphoid-to-myeloid ratio in bone marrow, although not altering their multilineage hematopoietic reconstitution potential after syngenic transplantation. Together with the frequent simultaneous deletions of KMT2A, ATM, and CBL and mutations of ASXL1, SF3B1, and CBL, we show that CADM1 may be important in the physiopathology of the del(11q) MDS, extending its role as tumor-suppressor gene from solid tumors to hematopoietic malignancies

    Overexpression of CEBPA resulting from the translocation t(14;19)(q32;q13) of human precursor B acute lymphoblastic leukemia

    No full text
    Subtle variation in the expression or function of a small group of transcription factors can drive leukemogenesis. The CEBPA protein is known to regulate the balance between cell proliferation and differentiation during early hematopoietic development and myeloid differentiation. In human myeloid leukemia, CEBPA is frequently inactivated by mutation and indirect and posttranslational mechanisms, in keeping with tumor suppressor properties. We report that CEBPA is activated by juxtaposition to the immunoglobulin gene enhancer upon its rearrangement with the immunoglobulin heavy-chain locus in precursor B-cell acute lymphoblastic leukemia harboring t(14;19)(q32;q13). Overexpression of apparently normal CEBPA RNA or protein was observed in 6 patients. These data indicate that CEBPA may exhibit oncogenic as well as tumor suppressor properties in human leukemogenesis.<br/

    Estimation de la sĂ©roprĂ©valence du VIH et de l’hĂ©patite C chez les usagers de drogues en France - Premiers rĂ©sultats de l’enquĂȘte ANRS-Coquelicot 2011

    No full text
    International audienceThe second edition of the Coquelicot survey aimed to describre drug users’ (DUs) profiles and practices, estimate HIV and HCV seroprevalences, and assess harm reduction policies. The survey was conducted in 2011 with a method of random sampling including DUs enrolled in specializedservices from five different cities and two departments in France. The eligibility criteria were: having injected or snorted at least once in their life, being at least 18 years old, and speaking French. A blood sample was also collected from to DUs at the end of the interview. Among all DUs selected, 1,568 (75%) accepted to participate. Most of them were men and socially precarious. Mean age was 39 years old. HIV and HCV seroprevalences were respectively 10% and 44%, and varied by age and cities.HCV seroprevalence has decreased since the first edition of the survey in 2004, especially among young DUs (less than 30 years old). HIV seroprevalence remained stable. As injection behaviors are still very strong among the youngest DUs (56% of them under 30 years old had injected at least once in their life, and among them 53% had injected during the month prior to the interview), risk reduction efforts should continue.La deuxiĂšme Ă©dition de l’enquĂȘte Coquelicot avait pour objectifs de dĂ©crire les profils et les pratiques des usagers de drogues (UD), d’estimer la sĂ©roprĂ©valence du VIH et du VHC, et d’évaluer la politique de rĂ©duction des risques.L’enquĂȘte s’est dĂ©roulĂ©e en 2011 Ă  partir d’un Ă©chantillon alĂ©atoire d’UD recrutĂ©s dans des structures spĂ©cialisĂ©es de cinq agglomĂ©rations et de deux dĂ©partements français. Les conditions pour pouvoir participer Ă  l’enquĂȘte Ă©taient : avoir injectĂ© ou sniffĂ© au moins une fois dans la vie, ĂȘtre majeur et francophone. Un prĂ©lĂšvement biologique a Ă©tĂ© rĂ©alisĂ© auprĂšs des UD ayant rĂ©pondu au questionnaire. Les premiers rĂ©sultats montrent un taux de participation de 75%. Avec au final 1 568 personnes enquĂȘtĂ©es, l’échantillon se compose en majoritĂ© d’hommes. Une grande partie d’entre eux est dans une situation sociale prĂ©caire. La moyenne d’ñge est de 39 ans. Les sĂ©roprĂ©valences du VIH et du VHC sont de 10 et 44 % et varienten fonction de l’ñge et de la ville. La sĂ©roprĂ©valence du VHC est en baisse depuis la premiĂšre Ă©dition de l’enquĂȘte en 2004, en particulier chezles moins de 30 ans. Celle du VIH est stable. Les pratiques d’injection restant importantes chez les plus jeunes (56% des UD de moins de 30 ans ont dĂ©jĂ  injectĂ© au cours de la vie, dont 53% dans le dernier mois), les efforts en matiĂšre de rĂ©duction des risques doivent se poursuivre

    AccÚs au lait de donneuses en Suisse et création de la premiÚre banque de lait maternel romande au CHUV ::enjeux et perspectives

    No full text
    Le lait maternel (LM) est idĂ©al pour la croissance et la santĂ© des nourrissons. En l’absence de LM, le lait de donneuses (LD) est prĂ©fĂ©rable au lait artificiel pour les nouveau-nĂ©s (NN) Ă  risques, prĂ©maturĂ©s ou prĂ©sentant certaines pathologies, au vu de ses effets protecteurs. Les banques de lait (BL) collectent, sĂ©curisent, traitent et distribuent le LD. Il existe en Suisse une insuffisance et une inĂ©galitĂ© d’accĂšs au LD, faute de cadre national. Avec le soutien de l’État de Vaud, le CHUV et la Transfusion interrĂ©gionale de la Croix-Rouge suisse ouvriront en 2022 la premiĂšre BL romande. Cette BL propose un systĂšme novateur en Suisse, fondĂ© sur une complĂ©mentaritĂ© d’expertises, afin d’optimiser la qualitĂ© et la sĂ©curitĂ© du LD et de soutenir la promotion de l’allaitement et du don.Mother’s own milk (MOM) is ideal for infant growth and health. When MOM is unavailable, donor human milk (DHM), rather than infant formula, is recommended for at-risk, preterm or sick neonates (NN), in view of its protective effects. Human milk banks (HMB) collect, secure, process and distribute DHM. In Switzerland, there is insufficient and unequal access to DHM in the absence of a national policy framework. With the support of the State of Vaud, the CHUV and the Interregional Blood Transfusion of the Swiss Red Cross will open the first HMB in Romandy in 2022. This HMB offers an innovative system in Switzerland, based on complementary expertise, in order to guarantee the quality and safety of DHM and to support the promotion of breastfeeding and human milk donation

    Genetic differences between paediatric and adult Burkitt lymphomas

    No full text
    Dysregulation of MYC is the genetic hallmark of Burkitt lymphoma (BL) but it is encountered in other aggressive mature B-cell lymphomas. MYC dysregulation needs other cooperating events for BL development. We aimed to characterize these events and assess the differences between adult and paediatric BLs that may explain the different outcomes in these two populations. We analysed patterns of genetic aberrations in a series of 24 BLs: 11 adults and 13 children. We looked for genomic imbalances (copy number variations), copy-neutral loss of heterozygosity (CN-LOH) and mutations in TP53, CDKN2A, ID3 (exon 1), TCF3 (exon17) and CCND3 (exon 6). Young patients displayed more frequent 13q31.3q32.1 amplification, 7q32q36 gain and 5q23.3 CN-LOH, while 17p13 and 18q21.3 CN-LOH were only detected in adult BLs. ID3 mutations were present in all adult samples, but only in 42% of childhood cases. CCND3 and ID3 double-hit mutations, as well as 18q21 CN-LOH, seemed to be associated with poorer outcome. For the first time, we report different genetic anomalies between adult and paediatric BLs, suggesting age-related heterogeneity in Burkitt lymphomagenesis. This may explain the poorer prognosis of adult BLs. Additional studies are needed to confirm these results in the setting of clinical trials.status: publishe
    corecore